The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
ConclusionsOur research demonstrates that there was no strong evidence showing that patients taking osimertinib as first-line treatment experienced longer median progression-free survival and overall survival than patients treated with afatinib. However, there was a statistical significance revealing that osimertinib provided better median progression-free survival than afatinib in patients with brain metastasis at baseline.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Statistics | Study | Taiwan Health